bpc-157 mitochondrial protection BPC-157: Tendon Repair and More Body Protecting Compound 157 (BPC-157

PMID 25204972 Systemic TB-4 failure in pigs - IV systemic TB-4 did not produce cardioprotection in a pig model

The unregulated research chemical market varies enormously in reliability

TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days

Consultation Answer a few questions about your symptoms and health history 100% online

With deep expertise, you can count on AFC Urgent Care for your vitamin B12 needs

Plug your vial size, BAC water amount, and target dose into the calculator and it will show you exactly how many units to draw